HEADER TRANSFERASE 07-DEC-21 7QG3 TITLE IRAK4 IN COMPLEX WITH INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: IRAK-4,RENAL CARCINOMA ANTIGEN NY-REN-64; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: IRAK4; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108 KEYWDS KINASE INHIBITOR INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 KEYWDS 2 INTERLEUKIN-1 SIGNALING, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR Y.XUE,A.AAGAARD,G.R.ROBB,S.L.DEGORCE REVDAT 2 31-JAN-24 7QG3 1 REMARK REVDAT 1 04-MAY-22 7QG3 0 JRNL AUTH I.A.CUMMING,S.L.DEGORCE,A.AAGAARD,E.L.BRAYBROOKE,N.L.DAVIES, JRNL AUTH 2 C.R.DIENE,A.J.EATHERTON,H.R.FELSTEAD,S.D.GROOMBRIDGE, JRNL AUTH 3 E.M.LENZ,Y.LI,Y.NAI,S.PEARSON,G.R.ROBB,J.S.SCOTT, JRNL AUTH 4 O.R.STEWARD,C.WU,Y.XUE,L.ZHANG,Y.ZHANG JRNL TITL IDENTIFICATION AND OPTIMISATION OF A PYRIMIDOPYRIDONE SERIES JRNL TITL 2 OF IRAK4 INHIBITORS. JRNL REF BIOORG.MED.CHEM. V. 63 16729 2022 JRNL REFN ESSN 1464-3391 JRNL PMID 35439688 JRNL DOI 10.1016/J.BMC.2022.116729 REMARK 2 REMARK 2 RESOLUTION. 2.11 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.11 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 44.42 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 93.3 REMARK 3 NUMBER OF REFLECTIONS : 37347 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.273 REMARK 3 R VALUE (WORKING SET) : 0.272 REMARK 3 FREE R VALUE : 0.304 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.050 REMARK 3 FREE R VALUE TEST SET COUNT : 1886 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 19 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.11 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.17 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 87.87 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2715 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2468 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2568 REMARK 3 BIN R VALUE (WORKING SET) : 0.2458 REMARK 3 BIN FREE R VALUE : 0.2627 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 5.41 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 147 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.000 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4452 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 66 REMARK 3 SOLVENT ATOMS : 30 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 55.53 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -11.06380 REMARK 3 B22 (A**2) : -7.31650 REMARK 3 B33 (A**2) : 18.38030 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.490 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.277 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.223 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.285 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.228 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.915 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.903 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4598 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 6213 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1629 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 132 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 651 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4598 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 595 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 5052 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.21 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 2.68 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 20.04 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7QG3 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 07-DEC-21. REMARK 100 THE DEPOSITION ID IS D_1292119532. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 07-JUL-17 REMARK 200 TEMPERATURE (KELVIN) : 100.000 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID30B REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.976 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS 0.5.32 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 39631 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.110 REMARK 200 RESOLUTION RANGE LOW (A) : 49.370 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 200 DATA REDUNDANCY : 8.100 REMARK 200 R MERGE (I) : 0.08500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 9.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.11 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.19 REMARK 200 COMPLETENESS FOR SHELL (%) : 95.4 REMARK 200 DATA REDUNDANCY IN SHELL : 5.90 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 0.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASES REMARK 200 STARTING MODEL: 6RFJ REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 50.35 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.48 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 2.7 M AMS 0.1 M HEPES PH 7.1-7.7, REMARK 280 EVAPORATION, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: I 2 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X,Y,-Z REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z+1/2 REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 43.66500 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 55.35500 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 71.16000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 43.66500 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 55.35500 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 71.16000 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 43.66500 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 55.35500 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 71.16000 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 43.66500 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 55.35500 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 71.16000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 153 REMARK 465 GLU A 154 REMARK 465 ASN A 155 REMARK 465 LYS A 156 REMARK 465 SER A 157 REMARK 465 LEU A 158 REMARK 465 GLU A 159 REMARK 465 VAL A 160 REMARK 465 SER A 161 REMARK 465 ASP A 162 REMARK 465 THR A 163 REMARK 465 GLY A 188 REMARK 465 GLY A 189 REMARK 465 ALA A 217 REMARK 465 MET A 218 REMARK 465 VAL A 219 REMARK 465 ASP A 220 REMARK 465 ILE A 221 REMARK 465 SER A 253 REMARK 465 ASP A 254 REMARK 465 GLY A 255 REMARK 465 ASP A 256 REMARK 465 SER A 336 REMARK 465 GLU A 337 REMARK 465 LYS A 338 REMARK 465 PHE A 339 REMARK 465 ALA A 340 REMARK 465 GLN A 341 REMARK 465 ALA A 459 REMARK 465 SER A 460 REMARK 465 GLY B 153 REMARK 465 GLU B 154 REMARK 465 ASN B 155 REMARK 465 LYS B 156 REMARK 465 SER B 157 REMARK 465 LEU B 158 REMARK 465 GLU B 159 REMARK 465 VAL B 160 REMARK 465 SER B 161 REMARK 465 ASP B 162 REMARK 465 THR B 163 REMARK 465 ALA B 216 REMARK 465 ALA B 217 REMARK 465 MET B 218 REMARK 465 VAL B 219 REMARK 465 ASP B 220 REMARK 465 ILE B 221 REMARK 465 GLU B 337 REMARK 465 LYS B 338 REMARK 465 PHE B 339 REMARK 465 ALA B 340 REMARK 465 GLN B 341 REMARK 465 TPO B 342 REMARK 465 ALA B 459 REMARK 465 SER B 460 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 180 58.54 31.38 REMARK 500 GLU A 182 83.23 -66.83 REMARK 500 ASN A 206 -85.37 71.43 REMARK 500 PHE A 251 -149.44 -156.64 REMARK 500 ARG A 310 -8.47 77.88 REMARK 500 ASP A 311 49.20 -142.81 REMARK 500 ASP A 329 100.85 58.47 REMARK 500 HIS A 390 40.04 -86.60 REMARK 500 ASP B 181 102.30 -58.51 REMARK 500 ASN B 207 -12.85 72.63 REMARK 500 PHE B 251 -153.57 -159.75 REMARK 500 SER B 252 75.20 -173.20 REMARK 500 ASP B 254 -77.86 -79.80 REMARK 500 ARG B 310 -8.31 78.83 REMARK 500 ASP B 311 48.28 -142.98 REMARK 500 ASP B 329 88.43 64.36 REMARK 500 LYS B 417 30.69 -80.67 REMARK 500 REMARK 500 REMARK: NULL DBREF 7QG3 A 154 460 UNP Q9NWZ3 IRAK4_HUMAN 154 460 DBREF 7QG3 B 154 460 UNP Q9NWZ3 IRAK4_HUMAN 154 460 SEQADV 7QG3 GLY A 153 UNP Q9NWZ3 EXPRESSION TAG SEQADV 7QG3 GLY B 153 UNP Q9NWZ3 EXPRESSION TAG SEQRES 1 A 308 GLY GLU ASN LYS SER LEU GLU VAL SER ASP THR ARG PHE SEQRES 2 A 308 HIS SER PHE SER PHE TYR GLU LEU LYS ASN VAL THR ASN SEQRES 3 A 308 ASN PHE ASP GLU ARG PRO ILE SER VAL GLY GLY ASN LYS SEQRES 4 A 308 MET GLY GLU GLY GLY PHE GLY VAL VAL TYR LYS GLY TYR SEQRES 5 A 308 VAL ASN ASN THR THR VAL ALA VAL LYS LYS LEU ALA ALA SEQRES 6 A 308 MET VAL ASP ILE THR THR GLU GLU LEU LYS GLN GLN PHE SEQRES 7 A 308 ASP GLN GLU ILE LYS VAL MET ALA LYS CYS GLN HIS GLU SEQRES 8 A 308 ASN LEU VAL GLU LEU LEU GLY PHE SER SER ASP GLY ASP SEQRES 9 A 308 ASP LEU CYS LEU VAL TYR VAL TYR MET PRO ASN GLY SER SEQRES 10 A 308 LEU LEU ASP ARG LEU SER CYS LEU ASP GLY THR PRO PRO SEQRES 11 A 308 LEU SER TRP HIS MET ARG CYS LYS ILE ALA GLN GLY ALA SEQRES 12 A 308 ALA ASN GLY ILE ASN PHE LEU HIS GLU ASN HIS HIS ILE SEQRES 13 A 308 HIS ARG ASP ILE LYS SER ALA ASN ILE LEU LEU ASP GLU SEQRES 14 A 308 ALA PHE THR ALA LYS ILE SER ASP PHE GLY LEU ALA ARG SEQRES 15 A 308 ALA SER GLU LYS PHE ALA GLN TPO VAL MET TPO SEP ARG SEQRES 16 A 308 ILE VAL GLY THR THR ALA TYR MET ALA PRO GLU ALA LEU SEQRES 17 A 308 ARG GLY GLU ILE THR PRO LYS SER ASP ILE TYR SER PHE SEQRES 18 A 308 GLY VAL VAL LEU LEU GLU ILE ILE THR GLY LEU PRO ALA SEQRES 19 A 308 VAL ASP GLU HIS ARG GLU PRO GLN LEU LEU LEU ASP ILE SEQRES 20 A 308 LYS GLU GLU ILE GLU ASP GLU GLU LYS THR ILE GLU ASP SEQRES 21 A 308 TYR ILE ASP LYS LYS MET ASN ASP ALA ASP SER THR SER SEQRES 22 A 308 VAL GLU ALA MET TYR SER VAL ALA SER GLN CYS LEU HIS SEQRES 23 A 308 GLU LYS LYS ASN LYS ARG PRO ASP ILE LYS LYS VAL GLN SEQRES 24 A 308 GLN LEU LEU GLN GLU MET THR ALA SER SEQRES 1 B 308 GLY GLU ASN LYS SER LEU GLU VAL SER ASP THR ARG PHE SEQRES 2 B 308 HIS SER PHE SER PHE TYR GLU LEU LYS ASN VAL THR ASN SEQRES 3 B 308 ASN PHE ASP GLU ARG PRO ILE SER VAL GLY GLY ASN LYS SEQRES 4 B 308 MET GLY GLU GLY GLY PHE GLY VAL VAL TYR LYS GLY TYR SEQRES 5 B 308 VAL ASN ASN THR THR VAL ALA VAL LYS LYS LEU ALA ALA SEQRES 6 B 308 MET VAL ASP ILE THR THR GLU GLU LEU LYS GLN GLN PHE SEQRES 7 B 308 ASP GLN GLU ILE LYS VAL MET ALA LYS CYS GLN HIS GLU SEQRES 8 B 308 ASN LEU VAL GLU LEU LEU GLY PHE SER SER ASP GLY ASP SEQRES 9 B 308 ASP LEU CYS LEU VAL TYR VAL TYR MET PRO ASN GLY SER SEQRES 10 B 308 LEU LEU ASP ARG LEU SER CYS LEU ASP GLY THR PRO PRO SEQRES 11 B 308 LEU SER TRP HIS MET ARG CYS LYS ILE ALA GLN GLY ALA SEQRES 12 B 308 ALA ASN GLY ILE ASN PHE LEU HIS GLU ASN HIS HIS ILE SEQRES 13 B 308 HIS ARG ASP ILE LYS SER ALA ASN ILE LEU LEU ASP GLU SEQRES 14 B 308 ALA PHE THR ALA LYS ILE SER ASP PHE GLY LEU ALA ARG SEQRES 15 B 308 ALA SER GLU LYS PHE ALA GLN TPO VAL MET TPO SEP ARG SEQRES 16 B 308 ILE VAL GLY THR THR ALA TYR MET ALA PRO GLU ALA LEU SEQRES 17 B 308 ARG GLY GLU ILE THR PRO LYS SER ASP ILE TYR SER PHE SEQRES 18 B 308 GLY VAL VAL LEU LEU GLU ILE ILE THR GLY LEU PRO ALA SEQRES 19 B 308 VAL ASP GLU HIS ARG GLU PRO GLN LEU LEU LEU ASP ILE SEQRES 20 B 308 LYS GLU GLU ILE GLU ASP GLU GLU LYS THR ILE GLU ASP SEQRES 21 B 308 TYR ILE ASP LYS LYS MET ASN ASP ALA ASP SER THR SER SEQRES 22 B 308 VAL GLU ALA MET TYR SER VAL ALA SER GLN CYS LEU HIS SEQRES 23 B 308 GLU LYS LYS ASN LYS ARG PRO ASP ILE LYS LYS VAL GLN SEQRES 24 B 308 GLN LEU LEU GLN GLU MET THR ALA SER MODRES 7QG3 TPO A 342 THR MODIFIED RESIDUE MODRES 7QG3 TPO A 345 THR MODIFIED RESIDUE MODRES 7QG3 SEP A 346 SER MODIFIED RESIDUE MODRES 7QG3 TPO B 345 THR MODIFIED RESIDUE MODRES 7QG3 SEP B 346 SER MODIFIED RESIDUE HET TPO A 342 11 HET TPO A 345 11 HET SEP A 346 10 HET TPO B 345 11 HET SEP B 346 10 HET B4U A 501 33 HET B4U B 501 33 HETNAM TPO PHOSPHOTHREONINE HETNAM SEP PHOSPHOSERINE HETNAM B4U 6-[(2~{S})-2-FLUORANYLPROPYL]-4-[(1-METHYLCYCLOPROPYL) HETNAM 2 B4U AMINO]-2-[[1-(1-METHYLPIPERIDIN-4-YL)PYRAZOL-4- HETNAM 3 B4U YL]AMINO]PYRIDO[4,3-D]PYRIMIDIN-5-ONE HETSYN TPO PHOSPHONOTHREONINE HETSYN SEP PHOSPHONOSERINE FORMUL 1 TPO 3(C4 H10 N O6 P) FORMUL 1 SEP 2(C3 H8 N O6 P) FORMUL 3 B4U 2(C23 H31 F N8 O) FORMUL 5 HOH *30(H2 O) HELIX 1 AA1 SER A 169 THR A 177 1 9 HELIX 2 AA2 THR A 223 CYS A 240 1 18 HELIX 3 AA3 SER A 269 SER A 275 1 7 HELIX 4 AA4 CYS A 276 THR A 280 5 5 HELIX 5 AA5 SER A 284 ASN A 305 1 22 HELIX 6 AA6 LYS A 313 ALA A 315 5 3 HELIX 7 AA7 THR A 351 MET A 355 5 5 HELIX 8 AA8 ALA A 356 ARG A 361 1 6 HELIX 9 AA9 THR A 365 GLY A 383 1 19 HELIX 10 AB1 LEU A 395 LEU A 397 5 3 HELIX 11 AB2 ASP A 398 ASP A 405 1 8 HELIX 12 AB3 ASP A 422 LEU A 437 1 16 HELIX 13 AB4 LYS A 440 ARG A 444 5 5 HELIX 14 AB5 ASP A 446 THR A 458 1 13 HELIX 15 AB6 SER B 169 THR B 177 1 9 HELIX 16 AB7 PRO B 184 GLY B 188 5 5 HELIX 17 AB8 THR B 223 CYS B 240 1 18 HELIX 18 AB9 SER B 269 SER B 275 1 7 HELIX 19 AC1 CYS B 276 THR B 280 5 5 HELIX 20 AC2 SER B 284 ASN B 305 1 22 HELIX 21 AC3 LYS B 313 ALA B 315 5 3 HELIX 22 AC4 THR B 351 MET B 355 5 5 HELIX 23 AC5 ALA B 356 ARG B 361 1 6 HELIX 24 AC6 THR B 365 GLY B 383 1 19 HELIX 25 AC7 LEU B 395 LEU B 397 5 3 HELIX 26 AC8 ASP B 398 ASP B 405 1 8 HELIX 27 AC9 THR B 409 TYR B 413 5 5 HELIX 28 AD1 ASP B 422 LEU B 437 1 16 HELIX 29 AD2 LYS B 440 ARG B 444 5 5 HELIX 30 AD3 ASP B 446 THR B 458 1 13 SHEET 1 AA1 5 LYS A 191 GLY A 195 0 SHEET 2 AA1 5 GLY A 198 VAL A 205 -1 O VAL A 200 N GLY A 193 SHEET 3 AA1 5 THR A 208 LEU A 215 -1 O VAL A 210 N GLY A 203 SHEET 4 AA1 5 LEU A 258 VAL A 263 -1 O LEU A 260 N LYS A 213 SHEET 5 AA1 5 LEU A 248 GLY A 250 -1 N LEU A 249 O VAL A 261 SHEET 1 AA2 2 ILE A 317 LEU A 319 0 SHEET 2 AA2 2 ALA A 325 ILE A 327 -1 O LYS A 326 N LEU A 318 SHEET 1 AA3 2 VAL A 343 MET A 344 0 SHEET 2 AA3 2 GLU A 363 ILE A 364 -1 O ILE A 364 N VAL A 343 SHEET 1 AA4 6 HIS B 166 SER B 167 0 SHEET 2 AA4 6 LEU B 248 SER B 252 1 O LEU B 249 N HIS B 166 SHEET 3 AA4 6 CYS B 259 VAL B 263 -1 O VAL B 261 N LEU B 249 SHEET 4 AA4 6 THR B 208 LYS B 214 -1 N LYS B 213 O LEU B 260 SHEET 5 AA4 6 VAL B 199 VAL B 205 -1 N VAL B 205 O THR B 208 SHEET 6 AA4 6 LYS B 191 GLU B 194 -1 N MET B 192 O VAL B 200 SHEET 1 AA5 2 HIS B 307 ILE B 308 0 SHEET 2 AA5 2 ARG B 334 ALA B 335 -1 O ARG B 334 N ILE B 308 SHEET 1 AA6 2 ILE B 317 LEU B 319 0 SHEET 2 AA6 2 ALA B 325 ILE B 327 -1 O LYS B 326 N LEU B 318 LINK C TPO A 342 N VAL A 343 1555 1555 1.35 LINK C MET A 344 N TPO A 345 1555 1555 1.35 LINK C TPO A 345 N SEP A 346 1555 1555 1.35 LINK C SEP A 346 N ARG A 347 1555 1555 1.36 LINK C MET B 344 N TPO B 345 1555 1555 1.35 LINK C TPO B 345 N SEP B 346 1555 1555 1.35 LINK C SEP B 346 N ARG B 347 1555 1555 1.36 CISPEP 1 GLU A 392 PRO A 393 0 0.06 CISPEP 2 GLU B 392 PRO B 393 0 -0.54 CRYST1 87.330 110.710 142.320 90.00 90.00 90.00 I 2 2 2 16 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011451 0.000000 0.000000 0.00000 SCALE2 0.000000 0.009033 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007026 0.00000